MAYBAKER Stock Overview
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
May & Baker Nigeria plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₦7.00 |
| 52 Week High | ₦10.00 |
| 52 Week Low | ₦5.43 |
| Beta | 0.0093 |
| 1 Month Change | -19.54% |
| 3 Month Change | -25.53% |
| 1 Year Change | 13.82% |
| 3 Year Change | 59.09% |
| 5 Year Change | 159.26% |
| Change since IPO | 422.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAYBAKER | NG Pharmaceuticals | NG Market | |
|---|---|---|---|
| 7D | -1.4% | 4.5% | 0.5% |
| 1Y | 13.8% | -19.3% | 2.3% |
Return vs Industry: MAYBAKER exceeded the NG Pharmaceuticals industry which returned -21.8% over the past year.
Return vs Market: MAYBAKER exceeded the NG Market which returned 2.6% over the past year.
Price Volatility
| MAYBAKER volatility | |
|---|---|
| MAYBAKER Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in NG Market | 11.1% |
| 10% least volatile stocks in NG Market | 3.8% |
Stable Share Price: MAYBAKER's share price has been volatile over the past 3 months compared to the NG market.
Volatility Over Time: MAYBAKER's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of NG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 396 | Patrick Ajah | may-baker.com |
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products.
May & Baker Nigeria plc Fundamentals Summary
| MAYBAKER fundamental statistics | |
|---|---|
| Market cap | ₦12.08b |
| Earnings (TTM) | ₦1.62b |
| Revenue (TTM) | ₦28.91b |
7.5x
P/E Ratio0.4x
P/S RatioIs MAYBAKER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAYBAKER income statement (TTM) | |
|---|---|
| Revenue | ₦28.91b |
| Cost of Revenue | ₦20.98b |
| Gross Profit | ₦7.92b |
| Other Expenses | ₦6.30b |
| Earnings | ₦1.62b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 27.42% |
| Net Profit Margin | 5.61% |
| Debt/Equity Ratio | 48.4% |
How did MAYBAKER perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 19:48 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
May & Baker Nigeria plc is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yori Olutimayin | BGL Research |
| Christian Orajekwe | Cordros Capital Ltd. |
| null null | Cordros Capital Ltd. |